STRENGTH (Completed)
Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
- Medicine
- epanova
- Population
- ASCVD
- Phase
- III
- Starting year
- 2013
- More information
- ClinicalTrials.gov